Finasteride for Women: A Review of the Clinical Trial Evidence
Medically reviewed by [Reviewer Name, MD, Dermatology] | Last reviewed: August 2026 | Editorial policy | Finasteride for women guide
Note: Finasteride is not FDA-approved for use in women in the US. All clinical use in women represents off-label prescribing. This page presents research evidence only and is not medical advice.
The clinical trial evidence for finasteride in women with androgenetic alopecia (FAGA) is mixed. Early key trials were negative, but subsequent trials at higher doses showed promising results. Prescribing patterns differ by country.
Key Clinical Trials
| Trial | Population | Dose | Duration | Primary Outcome |
|---|---|---|---|---|
| Price VH et al., 2000 | 137 postmenopausal women | 1 mg/day | 12 months | Negative: No significant difference from placebo; trial halted early due to futility |
| Iorizzo M et al., 2006 | 37 premenopausal women on OCP; single group, no control | 2.5 mg/day | 12 months | Positive: Statistically significant improvement in scalp hair density vs. baseline; higher dose may be required |
| Yeon JH et al., 2011 | 87 normoandrogenic Asian women (pre- and postmenopausal) | 5 mg/day | 12 months | Hair density rose from 90 to 107 hairs/cm²; single arm, no placebo or comparison group |
Evidence Summary
- 1 mg/day is likely insufficient for most women; the negative key trials used this dose
- Doses of 2.5-5 mg/day show more consistent benefits in premenopausal women on adequate contraception
- Teratogenicity in male fetuses (Category X) necessitates reliable contraception in women of childbearing potential
Sources
- Price VH, et al. “Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.” J Am Acad Dermatol. 2000;43(5):768-776.
- Iorizzo M, et al. “Finasteride treatment of female pattern hair loss.” Arch Dermatol. 2006;142(3):298-302.